$PRTA

SCULLY WILLIAM P purchased $465K of PRTA

SCULLY WILLIAM P purchased 50,000 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $9.31 ($0.47M total) on 2026-06-04.

Original reporting
SEC EDGAR · SCULLY WILLIAM P
Published Jun 5, 2026, 5:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 5:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PRTA
Bullish
medium confidence
Mentioned
$PRTA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRTABullishLow
01

Why it matters

The disclosure may influence short-term sentiment and technical positioning, but it does not introduce new guidance, trial results, contracts, or litigation outcomes.

02

Market read

Track PRTA for any follow-on insider activity or corroborating fundamental catalysts; otherwise treat as low-impact sentiment data.

03

What to watch

The article notes no pre-arranged 10b5-1 plan, but it still provides no rationale, timing context, or follow-through buying/selling pattern.

Relevance 6/10Novelty 6/10Timing: today’s SEC Form 4 disclosure (filed 2026-06-05)

Background

The article is an SEC Form 4 insider transaction: a 10% owner purchased shares directly in the open market.

Company-level read

Ticker impact

$PRTABullishMedium confidence
Context

Prothena’s 10% owner bought 50,000 shares in an open-market transaction ($465.3K) disclosed via SEC Form 4.

Expected impact

Low, likely limited to short-term sentiment/flow rather than a durable repricing.

Evidence & confidence

The filing is a disclosed ownership change (Form 4) with no accompanying new company-specific operational or financial information.

Market effects

Minimal; this is company-specific insider activity with no stated sector/regulatory trigger.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (tax/portfolio rebalancing) and may not signal near-term fundamentals.

Key entities

  • PROTHENA CORP PUBLIC LTD CO

    Issuer of PRTA shares; subject of the insider transaction disclosure.

  • SCULLY WILLIAM P

    10% owner who purchased 50,000 PRTA shares at $9.3059/share.

Related articles

$PRTAMed

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena (PRTA) reported Q2 2026 adjusted loss per share of 32 cents, narrower than the Zacks estimate of a 39-cent loss. Revenues were $1.01 million versus $4.4 million a year earlier, mainly collaboration revenue from Bristol Myers Squibb (BMY) for PRX019. Prothena had $330.3 million cash, no debt, and reaffirmed 2026 net cash use guidance of $18-$23 million.

$PRTAMed

PROTHENA CORP PUBLIC LTD CO (PRTA): Results of Operations and Financial Condition

PROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026earningsre.htm EX-99.1 Document Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $25.7 million in the second quarter, and net cash provide